Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Aptivus

Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 20

HOS-114845 · Präparat HOS-094169

Inhibition of CYP 2D6 by tipranavir/r Antihistamines Astemizole Based on theoretical The concomitant use of Aptivus, Terfenadine considerations, tipranavir, co- co-administered with low dose No interaction study administered with low dose ritonavir, with astemizole or performed ritonavir, is expected to increase terfenadine is contraindicated due astemizole and terfenadine to potential serious and/or life concentrations. threatening events (see section 4.3) Inhibition of CYP 3A4 by tipranavir/r Ergot derivatives Dihydroergotamine Based on theoretical The concomitant use of Aptivus, Ergonovine considerations, tipranavir, co- co-administered with low dose Ergotamine administered with low dose ritonavir, with Methylergonovine ritonavir, is expected to increase dihydroergotamine, ergonovine, No interaction study dihydroergotamine, ergonovine, ergotamine or methylergonovine performed ergotamine and is contraindicated due to potential methylergonovine concentrations. serious and/or life threatening events (see section 4.3) Inhibition of CYP 3A4 by tipranavir/r Gastrointestinal motility agents Cisapride Based on theoretical The concomitant use of Aptivus, No interaction study considerations, tipranavir, co- co-administered with low dose performed administered with low dose ritonavir, with cisapride is ritonavir, is expected to increase contraindicated due to potential cisapride concentrations. serious and/or life threatening events (see section 4.3) Inhibition of CYP 3A4 by tipranavir/r

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): methylergonovine (HOS-086155) cisapride (HOS-085610) astemizole (HOS-085608) ergotamine (HOS-086154) ritonavir (HOS-084521) terfenadine (HOS-085607) ergonovine (HOS-086153) dihydroergotamine (HOS-086152)